Nintedanib Sandoz (Nintedanib)

Nintedanib acts on multiple receptor tyrosine kinases involved in fibrotic and oncogenic pathways, providing therapeutic benefit in several lung‑related conditions.

• Idiopathic pulmonary fibrosis (IPF): slows disease progression and reduces decline in forced vital capacity.
• Systemic sclerosis‑associated interstitial lung disease (SSc‑ILD): helps preserve lung function and delay respiratory failure.
• Non‑small cell lung cancer (NSCLC) in combination with chemotherapy: enhances overall response rates and may improve survival outcomes.

• Nintedanib inhibits a spectrum of receptor tyrosine kinases—including vascular endothelial growth factor receptors (VEGFR 1‑3), fibroblast growth factor receptors (FGFR 1‑3), and platelet‑derived growth factor receptors (PDGFR α/β). By blocking these pathways, it reduces fibroblast proliferation, angiogenesis, and extracellular matrix deposition, thereby limiting fibrotic remodeling and tumor‑associated vascular growth.

Nintedanib is associated with several adverse reactions that vary in frequency and severity.

Common Side Effects

• Diarrhea: frequent, watery stools that may require supportive care.
• Nausea: sensation of unease often accompanied by an urge to vomit.
• Vomiting: expulsion of stomach contents, sometimes severe.
• Decreased appetite: reduced desire to eat, potentially leading to weight loss.
• Abdominal pain: discomfort or cramping in the stomach region.
• Weight loss: unintended reduction in body weight.

Serious or Rare Side Effects

• Elevated liver enzymes: indicates possible hepatic injury, requiring monitoring.
• Bleeding events: increased risk of gastrointestinal or other hemorrhage.
• Cardiovascular events: includes hypertension, arterial thromboembolism.
• Severe infections: opportunistic or serious bacterial infections.
• Gastrointestinal perforation: rare but life‑threatening breach of the GI tract.
• Interstitial lung disease exacerbation: worsening of underlying lung disease.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for potential complications.

• Liver function monitoring: assess baseline enzymes and repeat periodically.
• Bleeding risk assessment: review anticoagulant or antiplatelet use.
• Cardiovascular evaluation: check blood pressure and cardiac history.
• Gastrointestinal symptom counseling: advise patients to report persistent diarrhea or abdominal pain.
• Drug interaction review: verify concomitant medications for CYP3A4 involvement.
• Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Nintedanib may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase nintedanib exposure.
• Anticoagulants (e.g., warfarin, direct oral anticoagulants): heightened bleeding risk.
• Antiplatelet agents (e.g., clopidogrel, high‑dose aspirin): additive hemorrhagic potential.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic levels.
• Statins metabolized by CYP3A4 (e.g., simvastatin, atorvastatin): monitor for myopathy.
• Diuretics: watch for electrolyte disturbances when combined with gastrointestinal fluid loss.